EyePoint Pharmaceuticals Dirección
Dirección controles de criterios 2/4
El CEO de EyePoint Pharmaceuticals' es Jay Duker , nombrado en Jan 2023, tiene una permanencia de 1.25 años. compensación anual total es $2.06M, compuesta por 25% salario y 75% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.1% de las acciones de la empresa, por valor de $839.01K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 3.3 años, respectivamente.
Información clave
Jay Duker
Chief Executive Officer (CEO)
US$2.9m
Compensación total
| Porcentaje del salario del CEO | 21.1% |
| Permanencia del CEO | 1.3yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 1.3yrs |
| Promedio de permanencia en la Junta Directiva | 3.4yrs |
Actualizaciones recientes de la dirección
Recent updates
EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31
EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06EyePoint Pharmaceuticals (NASDAQ:EYPT) Is Using Debt Safely
Sep 24Estimating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
Apr 02How Many EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Do Institutions Own?
Feb 22EyePoint Pharma announces potential capital raise
Feb 01Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$79m |
| Dec 31 2023 | US$3m | US$614k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$2m | US$515k | -US$102m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$3m | US$269k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$53k | n/a | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$52m |
| Mar 31 2020 | n/a | n/a | -US$51m |
| Dec 31 2019 | US$80k | n/a | -US$57m |
| Sep 30 2019 | n/a | n/a | -US$58m |
| Jun 30 2019 | n/a | n/a | -US$75m |
| Mar 31 2019 | n/a | n/a | -US$98m |
| Dec 31 2018 | US$27k | n/a | -US$86m |
| Sep 30 2018 | n/a | n/a | -US$80m |
| Jun 30 2018 | n/a | n/a | -US$53m |
| Mar 31 2018 | n/a | n/a | -US$25m |
| Dec 31 2017 | n/a | n/a | -US$23m |
| Sep 30 2017 | n/a | n/a | -US$17m |
| Jun 30 2017 | US$72k | n/a | -US$18m |
Compensación vs. Mercado: La compensación total ($USD2.92M) de Jay está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.42M).
Compensación vs. Ingresos: La compensación de Jay ha aumentado mientras la empresa no es rentable.
CEO
Jay Duker (64 yo)
1.3yrs
Permanencia
US$2,915,146
Compensación
Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. He served as C...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 1.3yrs | US$2.92m | 0.10% $ 627.7k | |
| Executive VP & CFO | 4.5yrs | US$1.78m | 0.084% $ 527.2k | |
| Interim Head of R&D and Director | less than a year | US$161.67k | 0.022% $ 137.8k | |
| Senior Vice President of Manufacturing & Operations | less than a year | sin datos | sin datos | |
| Chief Legal Officer & Company Secretary | 5.5yrs | sin datos | sin datos | |
| Chief People Officer & Senior VP of IT | 5.3yrs | sin datos | sin datos | |
| Senior VP & Chief Commercial Officer | 4.9yrs | US$1.46m | 0% $ 0 | |
| Chief Business Officer | less than a year | US$1.61m | 0.026% $ 165.2k | |
| Chief Regulatory Officer | 2.2yrs | sin datos | sin datos | |
| Senior Vice President of Program Leadership | less than a year | sin datos | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | sin datos |
1.3yrs
Permanencia media
57yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de EYPT no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | less than a year | US$2.92m | 0.10% $ 627.7k | |
| Interim Head of R&D and Director | 5.6yrs | US$161.67k | 0.022% $ 137.8k | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | sin datos | |
| Independent Non-Executive Chairman | 5.9yrs | US$214.78k | 0.016% $ 98.5k | |
| Independent Director | 4.8yrs | US$171.67k | 0.014% $ 89.5k | |
| Executive Vice-Chairman | 7.7yrs | US$3.74m | 0.40% $ 2.5m | |
| Independent Director | 5.3yrs | US$180.67k | 0.014% $ 89.5k | |
| Co- Chairman of Scientific Advisory Board | 2.8yrs | sin datos | sin datos | |
| Member of Executive Scientific Advisory Board | 2.8yrs | sin datos | sin datos | |
| Co-Chair of Scientific Advisory Board | 2.8yrs | sin datos | sin datos | |
| Director | 3.4yrs | sin datos | sin datos | |
| Member of Executive Scientific Advisory Board | 2.8yrs | sin datos | sin datos |
3.4yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de EYPT se considera experimentada (3.3 años de antigüedad promedio).